ADAP - Adaptimmune Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue59,50537,83314,19814,490
Cost of Revenue98,26987,38863,789-
Gross Profit-38,764-49,555-49,59114,490
Operating Expenses
Research Development-87,38863,78939,852
Selling General and Administrative43,60131,10623,20817,762
Non Recurring----
Others----
Total Operating Expenses141,870118,49486,99757,614
Operating Income or Loss-82,365-80,661-72,799-43,124
Income from Continuing Operations
Total Other Income/Expenses Net-12,65210,9742,1123,754
Earnings Before Interest and Taxes-82,365-80,661-72,799-43,124
Interest Expense----
Income Before Tax-95,017-69,687-70,687-39,370
Income Tax Expense497451892143
Minority Interest----
Net Income From Continuing Ops-95,514-70,138-71,579-39,513
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-95,514-70,138-71,579-39,513
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-95,514-70,138-71,579-48,176